Skip to main content

Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide.

Publication ,  Journal Article
Schuster, JM; Friedman, HS; Archer, GE; Fuchs, HE; McLendon, RE; Colvin, OM; Bigner, DD
Published in: Cancer Res
May 15, 1993

The addition of chemotherapy, notably using nitrosoureas, in the treatment of patients with glioblastoma multiforme has resulted in only modest improvements in long-term patient survival over the use of surgical intervention and irradiation alone. Intraarterial (i.a.) chemotherapy offers the potential benefit of increasing tumor drug delivery because of first-pass drug uptake, while minimizing systemic drug levels and toxicity. We have now investigated the i.a. therapy of intracerebral human glioma xenografts in athymic rats with 4-hydroperoxycyclophosphamide (4-HC), a preactivated derivative of cyclophosphamide. Athymic male rats were given intracerebral injections of the human glioma line D-54 MG. On Day 5 after injection, the rats were randomized (n = 8-10) by body weight (mean weight, approximately 300 g). In one set of experiments, each group received either i.v. saline, i.a. saline, 6 mg i.a. 4-HC, 6 mg i.v. 4-HC (6 mg), or 12 mg i.v. 4-HC. Intraarterial 4-HC produced significant increases in median survival (Day 24) compared with i.a. saline controls (140% increase), equivalent doses given i.v. (71% increase), and twice the equivalent dose given i.v. (50% increase) (by Wilcoxon rank sum analysis, P < 0.05 is statistically significant). The i.a. maximum tolerated dose was subsequently determined to be approximately 12.5 mg in non-tumor-bearing rats. Further experiments demonstrated a dose-response increase in survival for i.a. dosages of 6, 9, and 12.5 mg with significant improvement when compared with saline controls and 12.5 mg i.v. Pharmacokinetic experiments also demonstrated a significant first-pass uptake advantage for i.a. (versus i.v.) administered 4-HC. The short plasma half-life and marked antiglioma activity of 4-HC, without the need for hepatic activation, suggest a therapeutic application of this drug in the i.a. treatment of brain tumors.

Duke Scholars

Published In

Cancer Res

ISSN

0008-5472

Publication Date

May 15, 1993

Volume

53

Issue

10 Suppl

Start / End Page

2338 / 2343

Location

United States

Related Subject Headings

  • Transplantation, Heterologous
  • Rats, Nude
  • Rats
  • Oncology & Carcinogenesis
  • Mice, Nude
  • Mice
  • Male
  • Injections, Intravenous
  • Injections, Intra-Arterial
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Schuster, J. M., Friedman, H. S., Archer, G. E., Fuchs, H. E., McLendon, R. E., Colvin, O. M., & Bigner, D. D. (1993). Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide. Cancer Res, 53(10 Suppl), 2338–2343.
Schuster, J. M., H. S. Friedman, G. E. Archer, H. E. Fuchs, R. E. McLendon, O. M. Colvin, and D. D. Bigner. “Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide.Cancer Res 53, no. 10 Suppl (May 15, 1993): 2338–43.
Schuster JM, Friedman HS, Archer GE, Fuchs HE, McLendon RE, Colvin OM, et al. Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide. Cancer Res. 1993 May 15;53(10 Suppl):2338–43.
Schuster, J. M., et al. “Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide.Cancer Res, vol. 53, no. 10 Suppl, May 1993, pp. 2338–43.
Schuster JM, Friedman HS, Archer GE, Fuchs HE, McLendon RE, Colvin OM, Bigner DD. Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide. Cancer Res. 1993 May 15;53(10 Suppl):2338–2343.

Published In

Cancer Res

ISSN

0008-5472

Publication Date

May 15, 1993

Volume

53

Issue

10 Suppl

Start / End Page

2338 / 2343

Location

United States

Related Subject Headings

  • Transplantation, Heterologous
  • Rats, Nude
  • Rats
  • Oncology & Carcinogenesis
  • Mice, Nude
  • Mice
  • Male
  • Injections, Intravenous
  • Injections, Intra-Arterial
  • Humans